-
Je něco špatně v tomto záznamu ?
Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations
M. Casal Moura, P. Gauckler, HJ. Anders, A. Bruchfeld, GM. Fernandez-Juarez, J. Floege, E. Frangou, D. Goumenos, M. Segelmark, K. Turkmen, C. van Kooten, V. Tesar, D. Geetha, FC. Fervenza, DRW. Jayne, KI. Stevens, A. Kronbichler
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
PubMed
37164940
DOI
10.1093/ndt/gfad090
Knihovny.cz E-zdroje
- MeSH
- ANCA-asociované vaskulitidy * komplikace farmakoterapie MeSH
- chronické selhání ledvin * etiologie terapie MeSH
- Churgův-Straussové syndrom * MeSH
- glomerulonefritida * farmakoterapie MeSH
- granulomatóza s polyangiitidou * terapie MeSH
- lidé MeSH
- mikroskopická polyangiitida * terapie MeSH
- protilátky proti cytoplazmě neutrofilů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Updated guidelines on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were released in 2021 by the American College of Rheumatology jointly with the Vasculitis Foundation and, subsequently, in 2022 by the European Alliance of Associations for Rheumatology. In addition, in 2021, the Kidney Disease: Improving Global Outcomes had released updated recommendations on the treatment of AAV with glomerulonephritis (AAV-GN). Kidney involvement is particularly relevant in microscopic polyangiitis and granulomatosis with polyangiitis, but is less frequent in eosinophilic granulomatosis with polyangiitis. The management of AAV-GN has been a focus for drug development and change over the past 10 years. Avoidance of progression to end-stage kidney disease (ESKD) or kidney failure is one of the main unmet needs in the management of AAV, with ESKD having a major impact on morbidity, health costs and mortality risk. Relevant changes in AAV-GN management are related to remission-induction treatment of patients with severe kidney disease, the use of glucocorticoids and avacopan, and remission-maintenance treatment. All the documents provide guidance in accordance with the evidence-based standard of care available at the time of their release. With our work we aim to (i) show the progress made and identify the differences between guidelines and recommendations, (ii) discuss the supporting rationale for those, and (iii) identify gaps in knowledge that could benefit from additional research and should be revised in subsequent updates.
Department of Health Medicine and Caring Sciences Linköping University Linköping Sweden
Department of Internal Medicine 4 Hospital of the Ludwig Maximilians University Munich Germany
Department of Internal Medicine 4 Medical University Innsbruck Innsbruck Austria
Department of Medicine University of Cambridge Cambridge United Kingdom
Department of Nephrology and Renal Transplantation Patras University Hospital Patras Greece
Department of Nephrology Hospital Universitario La Paz IdiPAZ Madrid Spain
Department of Nephrology Limassol General Hospital SHSO Cyprus
Division of Nephrology Department of Internal Medicine Necmettin Erbakan University Konya Turkey
Division of Nephrology RWTH Aachen University Hospital Aachen Germany
Faculdade de Medicina da Universidade do Porto Departamento de Biomedicina Porto Portugal
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000965
- 003
- CZ-PrNML
- 005
- 20240213093528.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ndt/gfad090 $2 doi
- 035 __
- $a (PubMed)37164940
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Casal Moura, Marta $u Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA $u Faculdade de Medicina da Universidade do Porto, Departamento de Biomedicina, Porto, Portugal
- 245 10
- $a Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations / $c M. Casal Moura, P. Gauckler, HJ. Anders, A. Bruchfeld, GM. Fernandez-Juarez, J. Floege, E. Frangou, D. Goumenos, M. Segelmark, K. Turkmen, C. van Kooten, V. Tesar, D. Geetha, FC. Fervenza, DRW. Jayne, KI. Stevens, A. Kronbichler
- 520 9_
- $a Updated guidelines on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were released in 2021 by the American College of Rheumatology jointly with the Vasculitis Foundation and, subsequently, in 2022 by the European Alliance of Associations for Rheumatology. In addition, in 2021, the Kidney Disease: Improving Global Outcomes had released updated recommendations on the treatment of AAV with glomerulonephritis (AAV-GN). Kidney involvement is particularly relevant in microscopic polyangiitis and granulomatosis with polyangiitis, but is less frequent in eosinophilic granulomatosis with polyangiitis. The management of AAV-GN has been a focus for drug development and change over the past 10 years. Avoidance of progression to end-stage kidney disease (ESKD) or kidney failure is one of the main unmet needs in the management of AAV, with ESKD having a major impact on morbidity, health costs and mortality risk. Relevant changes in AAV-GN management are related to remission-induction treatment of patients with severe kidney disease, the use of glucocorticoids and avacopan, and remission-maintenance treatment. All the documents provide guidance in accordance with the evidence-based standard of care available at the time of their release. With our work we aim to (i) show the progress made and identify the differences between guidelines and recommendations, (ii) discuss the supporting rationale for those, and (iii) identify gaps in knowledge that could benefit from additional research and should be revised in subsequent updates.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a protilátky proti cytoplazmě neutrofilů $7 D019268
- 650 12
- $a granulomatóza s polyangiitidou $x terapie $7 D014890
- 650 12
- $a Churgův-Straussové syndrom $7 D015267
- 650 12
- $a ANCA-asociované vaskulitidy $x komplikace $x farmakoterapie $7 D056648
- 650 12
- $a mikroskopická polyangiitida $x terapie $7 D055953
- 650 12
- $a glomerulonefritida $x farmakoterapie $7 D005921
- 650 12
- $a chronické selhání ledvin $x etiologie $x terapie $7 D007676
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gauckler, Philipp $u Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria
- 700 1_
- $a Anders, Hans-Joachim $u Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University, Munich, Germany
- 700 1_
- $a Bruchfeld, Annette $u Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden $u Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Fernandez-Juarez, Gema M $u Department of Nephrology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
- 700 1_
- $a Floege, Jürgen $u Division of Nephrology, RWTH Aachen University Hospital, Aachen, Germany
- 700 1_
- $a Frangou, Eleni $u Department of Nephrology, Limassol General Hospital, SHSO, Cyprus; Medical School, University of Nicosia, Nicosia, Cyprus
- 700 1_
- $a Goumenos, Dimitrios $u Department of Nephrology and Renal Transplantation, Patras University Hospital, Patras, Greece
- 700 1_
- $a Segelmark, Marten $u Division of Nephrology, Department of Clinical Sciences Lund, Lund University and Skane University Hospital, Lund, Sweden
- 700 1_
- $a Turkmen, Kultigin $u Division of Nephrology, Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey
- 700 1_
- $a van Kooten, Cees $u Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Tesar, Vladimir $u Department of Nephrology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czechia
- 700 1_
- $a Geetha, Duvuru $u Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America
- 700 1_
- $a Fervenza, Fernando C $u Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
- 700 1_
- $a Jayne, David R W $u Department of Medicine, University of Cambridge, Cambridge, United Kingdom
- 700 1_
- $a Stevens, Kate I $u Division of Nephrology and Transplantation, Queen Elizabeth University Hospital, Glasgow, United Kingdom
- 700 1_
- $a Kronbichler, Andreas $u Department of Medicine, University of Cambridge, Cambridge, United Kingdom
- 773 0_
- $w MED00010288 $t Nephrology, dialysis, transplantation $x 1460-2385 $g Roč. 38, č. 11 (2023), s. 2637-2651
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37164940 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093525 $b ABA008
- 999 __
- $a ok $b bmc $g 2049536 $s 1210659
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 38 $c 11 $d 2637-2651 $e 2023Oct31 $i 1460-2385 $m Nephrology, dialysis, transplantation $n Nephrol Dial Transplant $x MED00010288
- LZP __
- $a Pubmed-20240109
